Bienvenidos al Grupo de Trabajo
GEDEFO

OTHER WORKGROUPS
SEFH HOME PAGE

gedefo slide 01

GEDEFO

Who are we?

CONSENSUS STATEMENTS AND POSITION PAPERS

10 COMMON CHALLENGES FACED BY HOSPITAL PHARMACY AND ONCOLOGY UNITS (2021)
CLINICAL INTERVIEW
2021-2025 STRATEGIC PLAN
RED C (C NETWORK) (2021)
THE CMO MODEL FOR CANCER AND HEMATOLOGICAL PATIENTS (2020)
SEFH’S POSITION PAPER ON THE NEW ANTINEOPLASTIC MEDICATIONS (2019)
CAR-T CELL THERAPY MANAGEMENT PROCEDURE (2019)
PHARMACEUTICAL VALIDATION OF MEDICAL PRESCRIPTIONS FOR HEMATO-ONCOLOGICAL PATIENTS (2018)
SEFH’S POSITION PAPER ON BIOSIMILAR DRUGS (2017)
STRATEGIC PLAN ON THE PHARMACEUTICAL CARE OF HEMATO-ONCOLOGICAL PATIENTS (2016)
POSITION PAPER ON THE ACCESS TO NEW ANTINEOPLASTIC MEDICATION (2015)
CONSENSUS STATEMENTS

DOCUMENTS

PATIENT INFORMATION
CHEMOTHERAPY MANAGEMENT PROTOCOLS
- EXTRAVASATION AND EFFUSIONS
- COLORRECTAL CANCER PROTOCOLS - NURSING
DISEASE MONOGRAPHS
EXTRAVASATION MONOGRAPHS
WHAT IS A BIOSIMILAR DRUG? (GTEII)
BRIEFING NOTES

LINKS OF INTEREST

GEDEFO PUBLISHING REGULATIONS
PUBLICATIONS

EDUCATIONAL ACTIVITIES

JOIN OUR WORKGROUP

Contact us

Search ...

JOIN OUR WORKGROUP

Print
Email

Sus datos podrán facilitarse a ESOP para beneficiarse de los acuerdos aplicados a Gedefo.

FOLLOW US ON X

Instagram

GEDEFO CARES

GEDEFO CARES

TOOLS

CALCULATORS
MOBILE APPS

NEWSLETTERS

PAST NEWSLETTERS

ESOP

EUROPEAN SOCIETY OF ONCOLOGY PHARMACY

EBMT

EUROPEAN SOCIETY FOR BLOOD AND MARROW TRANSPLATATION

BPS PROJECT

BPS PROJECT

Copyright © Sociedad Española de Farmacia Hospitalaria - Desarrollado por ESM Consulting

Back to Top